Artivion chief commercial officer John E. Davis sells $356,548 in stock

On March 11, 2025, John E. Davis, the Chief Commercial Officer of Artivion, Inc. (NYSE:AORT), executed a series of stock transactions, as disclosed in a recent SEC filing. Davis sold 15,100 shares of common stock at a weighted average price of $23.6125, amounting to a total sale value of $356,548. The prices for these transactions ranged from $23.14 to $23.89. The stock, currently trading at $23.66, has shown significant volatility according to InvestingPro analysis of this nearly $1 billion market cap company.

In addition to the sale, Davis exercised stock options to acquire 15,910 shares at a price of $21.55 per share. This transaction was valued at $342,860. Following these transactions, Davis holds 208,778 shares directly. The sales were conducted under a 10b5-1 trading plan adopted on August 30, 2024. InvestingPro data shows Artivion maintains strong financial health with a current ratio of 4.34 and steady revenue growth of 9.75%. Discover more insights with InvestingPro’s comprehensive analysis, including 10+ additional ProTips and the detailed Pro Research Report.

In other recent news, Artivion Inc. reported a fourth-quarter revenue of $97.3 million for 2024, missing the forecasted $100.82 million due to a cybersecurity breach that impacted sales by approximately $4.5 million. Despite this setback, the company’s adjusted EBITDA exceeded expectations, reaching $17.6 million against the anticipated $17 million. For the full year 2024, Artivion’s revenue totaled $388.5 million, slightly below the guidance range, while adjusted EBITDA showed a significant 32% increase. Looking ahead, Artivion projects 2025 revenues between $420 million and $435 million, with adjusted EBITDA anticipated to be between $83 million and $91 million, reflecting optimism for a rebound in growth.

Analysts have responded to these developments with mixed adjustments. Stifel lowered its price target for Artivion from $33 to $30, maintaining a Buy rating, while Needham also reduced its target from $34 to $32 but kept a Buy rating, both citing the impact of the cybersecurity incident. JMP Securities, however, maintained a price target of $33 and a Market Outperform rating, emphasizing the company’s resilience and recovery efforts. The cybersecurity incident, while impacting short-term operations, is not expected to have a significant effect on Artivion’s full-year 2025 results, as the company aims to offset the first quarter’s challenges in subsequent quarters.

Artivion’s product performance varied, with the On-X line and stent grafts showing growth, while Preservation Services declined. The company saw notable growth in Latin America and the Asia Pacific regions, despite a slowdown in constant currency revenue growth in the fourth quarter. Artivion remains focused on innovation and market expansion, with key product launches anticipated to drive future growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.